Provided by Tiger Fintech (Singapore) Pte. Ltd.

Bristol-Myers Squibb

48.69
+0.16000.33%
Post-market: 48.60-0.0900-0.18%19:57 EDT
Volume:20.58M
Turnover:995.03M
Market Cap:99.07B
PE:-11.03
High:48.84
Open:47.94
Low:46.93
Close:48.53
Loading ...

Bristol-Myers Squibb Shares Down 7.6% After the Bell Following Announcement Its Cobenfy Schizophrenia Treatment Did Not Reach Statistical Significance in Phase 3 Trial

THOMSON REUTERS
·
23 Apr

Bristol Myers' Cobenfy fails to meet main goal as add-on treatment for schizophrenia

Reuters
·
23 Apr

Bristol-Myers Squibb Co - Cobenfy Safety and Tolerability Consistent With Previous Trials

THOMSON REUTERS
·
23 Apr

Bristol-Myers Squibb Co - Cobenfy Did Not Reach Statistical Significance in Phase 3 Trial

THOMSON REUTERS
·
23 Apr

Bristol Myers Squibb Announces Topline Results From Phase 3 Arise Trial Evaluating Cobenfy (Xanomeline and Trospium Chloride) as an Adjunctive Treatment to Atypical Antipsychotics in Adults With Schizophrenia

THOMSON REUTERS
·
23 Apr

Top Calls on Wall Street: Apple, Nvidia, Tesla, Amazon, Meta, Disney, McDonald’s & More

Tiger Newspress
·
22 Apr

Market Chatter: Trump Administration Mulls Cutting US Drug Prices to International Levels

MT Newswires Live
·
22 Apr

Trump Mulls Cutting US Drug Prices to International Levels, Reuters Reports

MT Newswires Live
·
22 Apr

NeoGenomics (NEO) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Zacks
·
22 Apr

FOCUS-Trump looking at cutting US drug prices to international levels, sources say

Reuters
·
22 Apr

Why Bristol Myers Squibb (BMY) is a Top Value Stock for the Long-Term

Zacks
·
22 Apr

Bristol-Myers Squibb Coverage Assumed by Cantor Fitzgerald at Neutral

Dow Jones
·
22 Apr

Bristol-Myers Squibb (BMY) Has a New Rating from Cantor Fitzgerald

TIPRANKS
·
22 Apr

Piper Sandler Initiates Bristol-Myers Squibb at Overweight With $65 Price Target

MT Newswires Live
·
22 Apr

Cytokinetics reiterated as top pick at H.C. Wainwright, Camzyos updates positive

TIPRANKS
·
21 Apr

Bristol-Myers Says US FDA Updates Prescribing Information for Cardiac Myosin Inhibitor Camzyos

MT Newswires Live
·
21 Apr

Bristol-Myers Squibb’s Camzyos: Regulatory Easing vs. Looming Competition

TIPRANKS
·
21 Apr

Curious about Bristol Myers (BMY) Q1 Performance? Explore Wall Street Estimates for Key Metrics

Zacks
·
18 Apr

Bristol Myers says FDA updates Camzyos label to simplify treatment

TIPRANKS
·
18 Apr

BRIEF-U.S. FDA Updates Camzyos Label To Reduce Echocardiography Monitoring Requirements And Contraindications

Reuters
·
18 Apr